Inadequate bowel preparation compromises colonoscopy quality and diagnostic accuracy, and cirrhosis is a recognized independent predictor of poor bowel cleansing. However, no bowel preparation regimen has been prospectively validated or specifically tailored for cirrhotic patients.
This multicenter, prospective, randomized, single-blind controlled clinical trial will evaluate whether the addition of adjunctive measures as an intensified bowel preparation protocol improves bowel cleansing quality in adult patients with cirrhosis undergoing elective outpatient colonoscopy.
Participants will be randomized 1:1 to receive either a standard bowel preparation protocol, consisting of a 2-litre split-dose polyethylene glycol (PEG) regimen combined with a one-day low-residue diet and clear liquids the afternoon before the procedure (control), or the same split-dose regimen with the assigned adjunctive measures: 15 mg bisacodyl, a 3-day low-residue diet, and clear liquids the day before colonoscopy (intervention).
The primary outcome is the proportion of patients achieving adequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) total score ≥6 with no individual segment score <2. Secondary outcomes include polyp, adenoma, advanced adenoma and colorectal cancer detection rates, caecal intubation rate, patient compliance, tolerability, and adverse events. Pre-specified subgroup analyses will evaluate the influence of etiology and severity of cirrhosis and portal hypertension complications.
By addressing a critical and unmet clinical need, this trial aims to generate high-quality evidence to optimize bowel preparation strategies in patients with cirrhosis, improve colonoscopy quality, and ultimately enhance colorectal cancer screening outcomes in this vulnerable population.

Start Date01 Aug 2026

Sponsor / Collaborator

Hospital do Divino Espírito Santo de Ponta Delgada EPE

NCT07351357

/ RecruitingPhase 4IIT

Multi-Centre Pragmatic Randomized Controlled Trial of Bowel Preparation Before Peritoneal Dialysis Catheter Insertion

Doctors need to insert catheter for patients who are going to have peritoneal dialysis. These peritoneal catheters can be obstructed or blocked afterward. The chance of not having smooth flow can be up to 12 and 31%. So far, constipation is one of the proposed reasons. Therefore, the study is aimed to investigate whether the preventive use of laxative before the surgery can help better improve the function of the catheter and hence better flow.

Start Date12 Jan 2026

Sponsor / Collaborator

The Chinese University of Hong Kong

PACTR202512709170316

/ SuspendedNot ApplicableIIT

Efficacy of bisacodyl suppository versus standard care in enhancing early recovery post cesarean section: A randomised controlled trial at Irrua Specialist Teaching Hospital, Irrua

Start Date04 Jan 2026

Sponsor / Collaborator-

100 Clinical Results associated with Bisacodyl

100 Translational Medicine associated with Bisacodyl

100 Patents (Medical) associated with Bisacodyl

792

Literatures (Medical) associated with Bisacodyl

01 Oct 2026·Journal of Advanced Research

Heat-inactivated probiotic-fermented tamarind pulp alleviates constipation by modulating gut tryptophan catabolism and the AhR NLRP3 axis

Article

Author: Liu, Xuebo ; Song, Zibo ; Yuan, Chunmei ; Huang, Siyan ; Liu, Zhijia ; Gui, Xi ; Wu, Lan ; Mu, Mingdao ; Wang, Tao ; Chu, Chuanqi ; Huang, Kaijun ; Yi, Junjie

INTRODUCTION:

Constipation is a common gastrointestinal disorder with gut dysbiosis, and existing laxatives often have limitations, necessitating the development of safer and more effective nutritional interventions.

OBJECTIVE:

This study aimed to investigate the alleviating effects and potential mechanisms of probiotic-fermented tamarind pulp (FTP) on loperamide-induced constipation in mice.

METHODS:

A constipated mouse model was established and treated with low and high-dose FTP (LD‑FTP and HD‑FTP). Assessments included gastrointestinal transit, histopathology, serum neurotransmitters/inflammatory factors, gut microbiota (16S rRNA amplicon sequencing), functional predictions generated using PICRUSt2, and fecal metabolomics (LC-MS).

RESULTS:

FTP dose-dependently alleviated loperamide‑induced constipation. Compared with the model group, HD‑FTP increased small intestinal transit rate by 57.2% (to 92.95%, p < 0.001) and fecal water content by 65.9% (to 70.52%, p < 0.001), both effects superior to the positive control bisacodyl. HD‑FTP also reduced serum IL‑6, IL‑1β, and TNF‑α by 60.0%, 43.5%, and 45.4%, respectively (all p < 0.001), and elevated total short-chain fatty acids (SCFAs) by 107.4% (p < 0.001). FTP exhibited significantly superior constipation‑alleviating efficacy compared to unfermented tamarind pulp (UFTP). FTP also increased microbial richness, enriched potentially beneficial SCFA-producing taxa, and restored microbial metabolic pathways associated with SCFA biosynthesis. Notably, fermentation enhanced tryptophan metabolism toward indole and serotonin pathways, which correlated with increased aryl hydrocarbon receptor (AhR) activation and reduced NLRP3 inflammasome signaling in the colon.

CONCLUSION:

FTP effectively alleviated constipation by improving intestinal function, reducing inflammation, and remodeling the gut microbiota-metabolite axis. Mechanistically, fermentation-driven tryptophan catabolism and quercetin biotransformation converge on the AhR-NLRP3 axis. These findings highlight FTP as a superior nutritional strategy over UFTP.

01 Oct 2026·GERIATRIC NURSING

Non-pharmacological dietary support for functional constipation in long-term care: A quasi-experimental pilot study of young barley leaf

Article

Author: Lai, Yi-Jiun ; Yang, Chih-Min

PURPOSE:

To evaluate the feasibility and short-term bowel-related changes associated with young barley leaf (YBL) supplementation among long-term care residents with functional constipation.

METHODS:

A one-group quasi-experimental pilot study was conducted in a long-term care facility. Twenty-eight residents who met the Rome IV criteria for functional constipation received YBL (3 g twice daily) for two weeks following a one-week baseline period. Defecation frequency, bisacodyl use, and bowel sounds were recorded daily by care staff and investigators. Selected biochemical parameters and gut hormone levels were assessed at baseline and post-intervention to provide a supportive physiological context.

RESULTS:

Defecation frequency increased significantly during the second week of supplementation compared with baseline (p < 0.05) and declined after discontinuation. Bowel sound frequency also increased significantly during the intervention period (p < 0.001). Although bisacodyl use did not change significantly, a downward trend was observed. YBL supplementation was well tolerated in this highly dependent population. Exploratory analyses showed changes in selected metabolic and gut hormone markers, although their clinical relevance remains to be clarified.

CONCLUSION:

In this pilot study, short-term YBL supplementation was feasible and was associated with favorable bowel-related changes among long-term care residents with functional constipation. Because this study used a one-group pretest-posttest design without a control group, the findings should be interpreted as preliminary and hypothesis-generating. Further controlled studies with larger samples and validated outcome measures are needed to confirm the potential role of YBL supplementation as a non-pharmacological dietary support strategy in long-term care.

09 Jul 2026·Current Computer-Aided Drug Design

Precision Network Pharmacology Revealed by High-throughput Blind Docking: Deciphering the Multitarget Synergy of Taohe Chengqi Decoction against Constipation

Article

Author: Chang, Xiaoli ; Wu, Xudong ; Wei, Daijing ; Yu, Linbing ; Gao, Yuan

Introduction::

Constipation, prevalent globally (16–35%), is particularly common in the elderly, reducing quality of life and causing complications like intestinal obstruction. Current treatments (e.g., methylcellulose, polyethylene glycol, bisacodyl, prucalopride) provide temporary relief but have side effects, such as electrolyte disturbances and drug dependence. It is worth noting that the traditional Chinese herbal drug Taohe Chengqi Decoction (TCD) has demonstrated good laxative efficacy and safety advantages in long-term clinical practice. However, its systematic mechanism of action involving multiple components, multiple targets, and multiple pathways remains unclear.

Methods::

This study innovatively integrates network pharmacology prediction, high-throughput blind molecular docking assisted by machine learning (DiffDock), and molecular dynamics simulation to construct a multidimensional mechanism model for TCD in treating constipation.

Results::

A total of 115 active molecules were identified from TCD through high-throughput blind docking and network pharmacology, targeting 153 constipation-related proteins. After an 80 ns molecular dynamics simulation, six core components demonstrated stable binding with key targets like AKT1 and MAPK3.

Discussions::

TCD exerts its therapeutic effects by intervening in key signaling pathways such as PI3K-Akt, IL-17 inflammation, T cell receptor, MAPK, and cAMP. It regulates the dynamic balance of intestinal epithelial cell proliferation/apoptosis, inhibits inflammatory cascades, and enhances intestinal motility and secretory functions to relieve constipation.

Conclusion::

The innovative integration of machine learning-driven high-throughput blind docking technology with network pharmacology establishes a novel paradigm for traditional Chinese medicine research, significantly enhancing target prediction reliability through advanced structural validation.

News (Medical) associated with Bisacodyl

16 Oct 2026

·www.opella.com

Press Release. Opella and World Allergy Organization launch five-year partnership to improve allergy care for millions worldwide.

Deep dive. Kyoto, Japan - 16 October 2026 - Opella, a global leader in consumer healthcare, and the World Allergy Organization (WAO), a worldwide federation of allergy and clinical immunology societies working to enhance global allergy education, today announced a five-year global partnership to improve how allergic diseases are recognized and managed in everyday care settings around the world. Running from 2027 through 2031, the partnership brings together expertise within the WAO global network of allergy societies with Opella's scientific expertise and leadership in self-care to support the clinicians who manage allergic disease most often: general practitioners, pediatricians, pharmacists, nurses and primary care teams. The announcement was made at the 32nd World Allergy Congress (WAC) in Kyoto, Japan where the two organizations also unveiled the first WAO-Opella Award for Innovative Solutions in Everyday Allergy Care. Opella and WAO will also collaborate on their first joint ‘Self-care in Allergy Report’ in December this year, shining a spotlight on the need for stronger awareness, earlier action and better support for people living with allergies. A key focus of the collaboration will be helping drive earlier recognition of allergic disease, support best-practice management, and spotlight innovative approaches that improve patient outcomes in everyday clinical settings. The new award will celebrate measurable improvements in how allergic disease is recognized and managed at this frontline level of care. The inaugural cycle will focus on care for children and adolescents, reflecting the significant and often under-recognized impact of allergic disease on sleep, school attendance and daily life. Entries will open in January 2027, with inaugural winners to be announced in mid-2027 and presented at the World Allergy Congress in October 2027. Allergic diseases affect a substantial and growing proportion of the global population, with a particularly important burden in children and adolescents. Allergic rhinitis alone affects hundreds of millions of people worldwide1 and remains frequently underdiagnosed and undertreated. Its impact extends well beyond symptoms, affecting sleep, school and work performance, wellbeing and quality of life. Earlier recognition, appropriate self-care, timely professional advice and clear referral pathways can help improve outcomes and reduce the broader burden of allergic disease.2 Dr. Josephine Fubara, Chief Science Officer of Opella. Healthcare professionals and pharmacists are often the first point of care for millions of people living with allergies. This new partnership combines Opella’s expertise in self-care with WAO’s scientific leadership to help advance allergy care globally. Through peer-to-peer healthcare professional engagement, education and health literacy initiatives, and the development of evidence-based allergy resources and care pathways, we aim to put health in people’s hands and give them the knowledge and resources they need to manage their allergies and health with confidence. Prof. Mário Morais-Almeida, President of the World Allergy Organization. Allergic diseases are often first recognized and managed far from the allergist's office – in primary care, pediatrics, pharmacies and community settings. The quality of that first interaction can shape the entire patient journey. This partnership will help bring evidence-based, WAO-endorsed guidance closer to the professionals who see these patients every day, while recognizing their essential role in patient-centered care and helping reduce gaps in access to high-quality allergy care worldwide. WAO will invite its global network of allergy societies to promote and participate in the partnership, alongside engagement with international key opinion leaders, with further details on upcoming health literacy programs and frontline initiatives to be shared in the months ahead. About Opella. Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. Opella is a certified B Corporation™, reflecting its commitment to high standards of social and environmental performance. Find out more about our mission at www.opella.com. About World Allergy Organization (WAO). World Allergy Organization (WAO) is a federation of 116 regional and national allergology and clinical immunology societies from around the world. By collaborating with its member societies, WAO provides educational programs, symposia, and lectureships to individual members in nearly 100 countries. Founded in 1951, WAO has successfully organized over 30 major congresses. Our mission, as a worldwide alliance of allergy/immunology societies, is to be a global resource and advocate for the specialty, while advancing awareness and excellence in clinical care through education, research, and training. Visit their website to learn more at www.worldallergy.org. Press Contacts. Justine Rohée. justine.rohee@opella.com. +33 6 86 47 85 60. Philippa Carnohan. philippa.carnohan@opella.com. +33 6 31 14 82 36. All trademarks mentioned in this press release are the property of Opella. pdf version.

07 Jul 2026

·www.opella.com

Press Release. Experts call for earlier recognition of fatty liver disease in people living with obesity.

Deep dive. Brussels, 7 July 2026 – At the Economics of Obesity and Metabolic Health Summit - hosted by Economist Enterprise and held on June 10 in Brussels with support from multiple organizations, including Opella and its liver brand Essentiale - healthcare experts, policymakers and public health leaders called for stronger policy action to address the growing burden of obesity and its co-morbidities. Particular attention was given to steatotic (“fatty”) liver disease as an often-overlooked consequence, with Prof. Jeffrey Lazarus (ISGlobal) and Prof. Norbert Stefan (Eberhard Karls University of Tübingen) highlighting the urgent need to elevate its visibility in public health agendas. They emphasized that improving awareness and earlier identification of individuals at increased metabolic risk are critical to enabling timely intervention and reducing long-term health system impact. Obesity is one of the fastest-growing public health challenges worldwide, with the global economic impact of obesity and metabolic disorders projected to exceed $4 trillion annually by 20351. Fatty liver disease is closely linked to obesity and impaired metabolic health, affecting approximately 70% to 80% of people living with obesity2. As obesity rates continue to increase, experts noted that the fatty liver is becoming more prevalent and is now recognized alongside cardiovascular disease and type 2 diabetes as a major obesity-related health concern. Key insights from the discussion: Prof. Norbert Stefan, Professor of Clinical and Experimental Diabetology at the University of Tübingen, highlighted the close relationship between obesity and fatty liver disease. He explained that fatty liver can be an important marker of impaired metabolic health and help identify individuals who may be more likely to develop obesity-related complications. Kwasi Boahene, Director of Health Systems at PharmAccess, emphasized that prevention is most effective when people have access to routine health checks, screening and follow-up care that enable earlier detection of metabolic health risks. Manuela Ripa, Member of the European Parliament, highlighted the need for stronger prevention policies and healthier food environments, stressing that investing in prevention can improve health outcomes while reducing long-term healthcare costs. Sohail Munshi, Joint Chief Medical Officer at Manchester University NHS Foundation Trust, emphasized the value of embedding prevention into routine healthcare interactions to help identify obesity-related risks earlier and support timely intervention. A common theme throughout the discussion was the need to improve awareness of fatty liver disease and its connection to obesity and metabolic health. Prof. Norbert Stefan. Professor of Clinical and Experimental Diabetology at the University of Tübingen. Not all people living with obesity face the same risk of developing obesity-related complications3. As healthcare systems face increasing pressure, it is becoming more important to identify those individuals at highest risk and intervene earlier. Fatty liver can be an important indicator of increased metabolic health risk, helping people and healthcare professionals recognize potential problems before more serious conditions develop. We have identified a fatty liver as the key characteristic that distinguishes people with healthy obesity from those with unhealthy obesity. These findings have also led to the recognition that, in addition to cardiovascular disease and type 2 diabetes, fatty liver disease is now also considered a condition for which the costs should be covered by the healthcare system. The discussion reinforced the importance of helping people better understand the links between obesity, metabolic health and fatty liver disease. Experts agreed that increasing awareness and recognising risk factors earlier could support more proactive health management and contribute to healthier populations in the years ahead. About Opella. Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet. Find out more about our mission at www.opella.com. Prof. Norbert Stefan. N.S. has received research support and materials from Opella to conduct a study in people with fatty liver disease and to attend the Economics of Obesity and Metabolic Health Summit; fees for consultancy and scientific talks from Allergan, AstraZeneca, Boehringer Ingelheim, Gilead, Genkyotex, GSK, Intercept Pharma, Lilly, Merck Sharpe & Dohme, Novartis, Novo Nordisk, Opella and Pfizer; and has received research support from AstraZeneca, Boehringer Ingelheim, DSM Nutritional Products and Roche Diagnostics; and serves as coleader in the German Diabetes Association Study group MASLD. Press contacts. Philippa Carnohan. philippa.carnohan@opella.com. +33 6 31 14 82 36. All trademarks mentioned in this press release are the property of Opella. pdf version.

15 Jun 2026

·www.opella.com

Press Release. New Report Identifies Major Opportunity for UK Pharmacies to Advance Men’s Health.

Deep dive. UK, 15 June 2026 – Opella. While nine out of ten men surveyed (92%1) use their local pharmacy, almost three-quarters (74%2) of them leave without ever discussing their health with a pharmacist, a new report has revealed. This disconnect highlights a significant opportunity to catch illnesses earlier and alleviate pressure on the NHS. The report, "An Unfilled Prescription," published by the Men’s Health Forum and supported by global consumer health leader Opella, highlights a critical opportunity to convert men's regular presence in pharmacies into greater engagement with preventative health services. With UK men’s life expectancy four years shorter than women's, and over a third dying before their 75th birthday, the findings underline the valuable role the pharmacy sector can play as part of a wider effort to improve men’s health. The research identified the main barriers preventing men from living healthier lives, which, according to the men surveyed, include: Discomfort discussing health issues in a public retail space (22%3). A perception that seeking help is a sign of weakness (33%). A common tendency to delay seeking medical advice (36%). This silence, however, can have serious consequences. Over half of the men surveyed (57%4) reported that failing to seek advice led to negative impacts on their lives, including missed work (15%) and strained personal relationships (12%). Jim Pollard, Men’s Health Forum. With the UK Government rightly hoping to leverage pharmacies to relieve pressure on the NHS, this report is a clear call to action. We are committed to ensuring all men can live healthier, longer lives, and the key message for men is that pharmacy is for you. It is a far better source of health advice and information than, for example, AI, which simply cannot be recommended. By addressing the specific barriers preventing men from seeking advice, we can unlock the potential of pharmacies to become the front door to the health system for them. In response to the findings, the Men’s Health Forum has developed a practical five-step plan to help pharmacies better engage men and transform their stores into trusted health hubs. The plan was developed with feedback from pharmacists, nearly all of whom reported facing barriers to engaging male customers. The report calls on pharmacies to: 1. Create a Welcoming Space. Designate a clearly advertised private consulting room to ensure confidentiality. 2. Appoint a Champion. Nominate a 'Men’s Health Champion' trained in discussing men's health issues. 3. Offer Dedicated Services. Introduce dedicated services like 'men's health MOTs' and other tailored check-ups. 4. Improve Access & Guarantee Privacy. Review opening hours and implement online booking systems to offer flexibility and discretion. 5. Engage the Community Proactively. Actively reach out to men in the local community rather than waiting for them to ask for help. Nick Linton, UK Country Head, Opella. Community pharmacies are the frontline of our health service, and we are committed to supporting them. We welcome these recommendations, which provide clear, actionable guidance. Ensuring pharmacy meets its full potential will require a collaborative effort across government, regulators, and companies like Opella, and we are ready to play our par. The report found that men are willing to engage if the environment is right. Around a quarter of men surveyed said they would be more likely to talk to a pharmacist if they knew the conversation was private (24%) and that they could be referred to the NHS if needed (26%). Jim Pollard at Men’s Health Forum, conclude: It is vital that we get this right. We stand ready to work with pharmacies to make sure this opportunity isn’t missed. About Opella. Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet. Find out more about our mission at www.opella.com About Men's Health Forum. The Men's Health Forum's mission is to improve the health of men and boys in England, Wales and Scotland. To this end, we carry out research, raise awareness, work to change health policy, share and encourage the latest good practice, work with other charities and provide health information and advice to men through our website, training, Men's Health Week and our Man Manuals. Find out more at https://www.menshealthforum.org.uk. Press Contacts. Charlotte Messer. Charlotte.Messer@opella.com. +447928700277. Laura Webster. Laura.Webster@opella.com. +447740935106. All trademarks mentioned in this press release are the property of Opella. Methodology: The research was conducted by Censuswide, among a sample of 1675 respondents aged 18-65. The data was collected between 24.10.2025 - 27.10.2025. Censuswide abides by and employs members of the Market Research Society and follows the MRS code of conduct and ESOMAR principles. Censuswide is also a member of the British Polling Council. pdf version.

100 Deals associated with Bisacodyl

External Link

KEGG	Wiki	ATC	Drug Bank
D00245	Bisacodyl	A06AG02 A06AB02	DB09020

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Constipation	-	Pfizer Inc.	01 Jan 1953

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Constipation - functional	Phase 3	Germany	Boehringer Ingelheim Pharma GmbH & Co., KG	09 Aug 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02977286 (CTgov)	Phase 4	Constipation	12	Polyethylene Glycols+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Naloxegol Oral Tablet+Senna 217 Mg Oral Tablet+Methylnaltrexone (Naloxegol Oral Tablet)	obqbnlfawe(xjibjfjsep) = bqtyiqovwy pxeldvgcvd (uzzmrjqxls, 25) View more	-	16 Feb 2023
				Placebo Oral Tablet+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Methylnaltrexone (Placebo Oral Tablet)	obqbnlfawe(xjibjfjsep) = nyeupofxwy pxeldvgcvd (uzzmrjqxls, 25) View more
NCT02976805 (Pubmed \| Clin Gastroenterol Hepatol)	Phase 3	-	196	PEG 2 liters the evening before and 2 liters the day of colonoscopy (PEG 2+2L+bisacodyl)	sbtzfzjzbd(jlmvgbrexo) = zuvdhmmqgi hdbhuirxrx (yeoibdvped ) View more	-	01 Jun 2022
				4 liters and 2 liters (PEG 4+2L+bisacodyl)	sbtzfzjzbd(jlmvgbrexo) = rmhkgiwebq hdbhuirxrx (yeoibdvped ) View more
NCT02609607 (CTgov)	Phase 2	Fecal Incontinence \| Multiple Sclerosis \| Chronic constipation ... View more	11	Placebo (Placebo)	ffnnbhjydu = xlrpbckpga hoqxpahqnk (ubkqciqmeu, gzvstgkxae - tnfuilhaen) View more	-	22 Jan 2020
				Bisacodyl (Bisacodyl)	ffnnbhjydu = nyuncjixhi hoqxpahqnk (ubkqciqmeu, tivdmnckcx - ubaqxhsyei) View more
NCT02383758 (CTgov)	Not Applicable	Autism Spectrum Disorder \| Autistic Disorder \| Stool soiling	22	Glycerin Suppository+Bisacodyl suppository+Senna (Treatment Program)	unjetcrjrf = vtxqywawps bpytphtejp (uelhtzbsds, cremqeilia - pjxpquvqzf) View more	-	11 Jan 2018
				Glycerin Suppository+Bisacodyl suppository+Senna (Waitlist Control)	unjetcrjrf = hmvlhaajql bpytphtejp (uelhtzbsds, jbnzixipku - njuiumduem) View more
NCT02481219 (CTgov)	Not Applicable	Colorectal Cancer	122	SUPREP oral sulfate solution+Erythromycin+PEG+Metoclopramide+Bisacodyl+Senna tablets (Bowel Preparation Regimen -Control)	bacmcpsjoh = sceglngwwj mafbclmjtk (dpbpdznelp, ixrxutiyxg - hqfjzkypzh) View more	-	11 Jul 2016
				SUPREP oral sulfate solution with Gastrografin+Erythromycin+PEG+Metoclopramide+Bisacodyl+Senna tablets (Bowel Preparation Regimen-Test)	bacmcpsjoh = wigmdscbru mafbclmjtk (dpbpdznelp, hoiqrjzpkk - uhprzkoayo) View more
NCT01917773 (CTgov)	Phase 4	Chronic constipation \| Constipation	13	octreotide (15 Minutes)	haxewwrtnx(iuqfyopilr) = souxmyengb rmqsaeqjxq (wqctdjtywq, wupqiruigb - kvqxuymhhv) View more	-	21 Dec 2015
				octreotide (30 Minutes)	haxewwrtnx(iuqfyopilr) = snwcwcjolk rmqsaeqjxq (wqctdjtywq, mklvphteig - idskysixlb) View more
NCT01044212 (CTgov)	Not Applicable	Intestinal Diseases \| Enterocele	72	Polyethylene glycol+Dulcolax+Colace	fssnnzrxxe(gqyynodgfg) = romvijwcgn dfstfwfcxo (xkqejbpifi, 21) View more	-	21 Oct 2015
NCT01073943 \| NCT01073930 (SEE CLEAR I \| SEE CLEAR II, ECCO2014)	Phase 3	Intestinal preparation	-	P/MC Split-dose	tafgvfmzfr(wagbxhnqvs) = Both dosing regimens of P/MC were equally effective at bowel cleansing in all pts, regardless of age eflgimoldc (xdnpwgoulx ) View more	Positive	01 Feb 2014
				P/MC Day Before
NCT01063049 (CTgov)	Phase 4	Colonic Diseases	600	NuLytely (Nulytely)	kxofsdyslm(lpnncnpazh) = mpzqngsftm yuboptggau (xxswqxkfjc, 1.55) View more	-	18 Nov 2013
				Placebo+Miralax (Gatorade/Miralax + Placebo)	kxofsdyslm(lpnncnpazh) = idbdxaljpm yuboptggau (xxswqxkfjc, 1.28) View more
NCT00953017 (CTgov)	Phase 4	-	425	Amitiza (Miralax Plus Amitiza)	orbyljzwko(heixdgabnk) = watcdoovjy opukmppndt (gaofcndasa, hdkpupnzzw - stvfxibhmm) View more	-	30 Nov 2012
				Bisacodyl (Miralax Plus Dulcolax)	orbyljzwko(heixdgabnk) = frtsulcena opukmppndt (gaofcndasa, ueqegavopg - yjiiqbleod) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis